RESUMEN
We describe a case of genital ulcer and inguinal adenopathies that were attributable to monkeypox virus infection. We suggest clinicians adopt a low threshold for suspicion, particularly when evaluating genital ulcer disease.
Asunto(s)
Enfermedades Genitales , Herpes Genital , Mpox , Úlcera Péptica , Enfermedades Urogenitales , Humanos , Úlcera/diagnóstico , Diagnóstico Diferencial , Mpox/diagnóstico , GenitalesRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Sarcoma de Kaposi/diagnóstico , Serodiagnóstico del SIDA/métodos , VIH/patogenicidad , Sarcoma de Kaposi/inmunología , Sarcoma de Kaposi/tratamiento farmacológico , Antirretrovirales , Emigrantes e InmigrantesRESUMEN
Vemurafenib, a kinase inhibitor that targets tumors with the BRAF V600E mutation, is a promising option for unresectable or metastatic melanoma. Cutaneous side-effects have been reported including alopecia, photosensitivity, squamous cell carcinoma, keratoacanthomas, keratosis pilaris-like eruption, and palmoplantar hyperkeratosis. Acneiform eruptions have been reported in 3%-6% of the patients treated with BRAF inhibitors,and 5 cases are described in the literature. Although they responded well to topical therapies, oral antibiotics, or observation, one case required oral etretinate and the withdrawal of vemurafenib because the adverse event reached grade 3. We report one case of a severe acneiform eruption associated with vemurafenib with a good response to isotretinoin allowing continuation of the BRAF inhibitor.